You are using an older browser version. Please use a supported version for the best MSN experience.

Bayer, Zydus extend pharma JV by 3 years

The Times of India logo The Times of India 21-06-2021 टाइम्स न्यूज़ नेटवर्क
logo © Provided by The Times of India

Mumbai: German chemical and pharma major Bayer and Ahmedabad-based Cadila Healthcare on Monday extended their pharmaceuticals joint venture by three years from June 2021. The companies first entered into an agreement in January 2011 to set up Bayer Zydus Pharma for sales and marketing of pharmaceuticals in the country, the company said.

During the term of the joint venture, the company launched Bayer’s global assets including Xarelto, Eylea and Visanne. Bayer Zydus Pharma will continue to operate in core therapies including cardiovascular diseases, diabetes, women’s health, ophthalmology and oncology, with new products in the pipeline. Key products in the company’s pharmaceutical portfolio include Xarelto, Glucobay, Eylea, Yaz, Mirena and Visanne, the company added.

Bayer Zydus Pharma operates across the core business units of general medicine, women’s healthcare and specialty medicine for cardiovascular diseases, anti-diabetic treatments, ophthalmology, oncology and radiology, with new products in the pipeline.

More from The Times of India

The Times of India
The Times of India
image beaconimage beaconimage beacon